Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News COMPASS Pathways Plc CMPS

Healthcare Biotechnology
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary... see more

Recent & Breaking News (NDAQ:CMPS)

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

Business Wire October 31, 2024

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Business Wire October 24, 2024

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

Business Wire September 23, 2024

Compass Pathways announces second quarter 2024 financial results and business highlights

GlobeNewswire August 1, 2024

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

GlobeNewswire June 26, 2024

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire May 8, 2024

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

GlobeNewswire May 8, 2024

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

GlobeNewswire May 2, 2024

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

GlobeNewswire April 29, 2024

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

GlobeNewswire March 28, 2024

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights 

GlobeNewswire February 29, 2024

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

GlobeNewswire January 16, 2024

Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement

GlobeNewswire January 5, 2024

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

GlobeNewswire December 19, 2023

Compass Pathways appoints Teri Loxam as Chief Financial Officer

GlobeNewswire December 7, 2023

Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry

GlobeNewswire December 6, 2023

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

GlobeNewswire November 15, 2023

COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights

GlobeNewswire November 2, 2023

COMPASS Pathways announces CFO transition

GlobeNewswire October 26, 2023

The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It

TheNewsWire October 12, 2023